newsfilter
← Latest News
GlobeNewswire·

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC)